Drug Profile
Research programme: p53-HDM2 inhibitors - Ascenta Therapeutics
Alternative Names: MI-147; MI-219; MI-43; MI-519-64; MI-63Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Ascenta Therapeutics
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Jun 2010 Drug candidates from the research programme licensed to sanofi-aventis worldwide ,
- 11 Dec 2007 Pharmacodynamics data from a preclinical study in cancer presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)